Focus Partners Wealth’s Pacific Biosciences PACB Stock Holding History

Focus Partners Wealth’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.9K	Buy	+10,077	New	+$14.7K	﹤0.01%	2741

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Focus Partners Wealth's PACB Position: Q2 2026 in Review

Focus Partners Wealth opened a new position in Pacific Biosciences (PACB) in Q2 2026: 10,077 shares worth $16.9K. The stake represents ﹤0.01% of the portfolio and ranks #2741 among its holdings.

223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Focus Partners Wealth held 10,077 shares of Pacific Biosciences worth $16.9K as of Q2 2026.
Pacific Biosciences was a new Focus Partners Wealth position in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2741 holding.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.